Over the past five years, the cosmetic industry has met with several legislative changes. Within the new legislative package, including the new REACH and CLP, it is important to find a comfortable routine that will minimize costs while staying effective and compliant with all regulations.
Interview: East vs. West – Is there a regional approach to PPM in the US?
Read the full interview with Leigh Shultz, PhD, PMP, Associate Vice President, Project Management – Primary Care, Infectious Disease, Vaccines, Global Project & Alliance Management, Merck and gain insight into the regional approach to PPM across the US.
1. What are the main differences in (pharma/biopharma) PPM between East and West cost of US?
The differences are not clear to me. We all work in the same business – many large pharma are now bi-coastal, and the biopharma culture on the west coast is now being replicated in Boston, for example. This should be cutting down on regionalization or differences, and yet the two PM communities don’t operate as one for some reason.
2. What are the tendencies? Are we heading to unification?
There is a perception that the west coast is more bio-pharma rather than traditional big pharma or more innovative/entrepreneurial. I think this may just be a perception, but the perception may be enough to influence the process mindset and project management approach in the companies.
3. How can the size of a company influence PPM strategies across more regions?
This depends on both the size of the company, its footprint, and its approach. For R&D PM, it depends more on where R&D is located and the size of the portfolio than size of the company per se.
4. What is the standpoint of Merck to regional differences in PPM strategies?
Merck’s R&D PM expertise is located in HQ in the US northeast, and we tend to be active in networking with other PM organizations in our region. We would like to make this a more global PM community – at a minimum, looking at approaches and opening dialogue across the industry in the US, regardless of region. It’s not clear why barriers might exist – perception only, time differences, culture, company size…?
Interested in this topic?
Advanced Protein Aggregation & Characterization
This training will focus on occurrence of particles in drug products, effects of protein aggregates, critical process and parameters. Attendees will gain overview of on utility and limits of predictive experiments, learn concerns from the authorities and relevant aggregation guidelines, and more.
CMC Analytical Comparability: Methods & Strategies for Biologics, Biosimilars & Biobetters
Attendees will be introduced to comparability in biosimilar development, the analytical strategies of protein characterization of biosimilars, the structure of proteins, in vitro pharmacology and much more.
Corporate Compliance & Transparency in the Pharmaceutical Industry
This two-day conference will serve as a platform for an open and dynamic dialogue with HCPs and patients to achieve common goals. Learn how to embed compliance in the business and develop one simple system for managing compliance & transparency in a complex and regulated environment.
Strategize your Risk Management Plan in 2 steps
Read below the interview with Judy to reveal the latest trends in risk management and find out what are the most important steps towards strategizing your risk management plan.
A prescription of Quality and Efficiency in the right doses
Read below the interview with Ronan to understand the importance of balance between quality and efficiency and reveal which pitfalls to avoid.
10 ways to improve patient experience
Take a look at the inforgraphic about "10 ways to improve patient experience".